TY - JOUR T1 - Portable Objective Diagnostics using Visual Evoked Potentials for Age-related Macular Degeneration JF - medRxiv DO - 10.1101/2020.01.03.20016451 SP - 2020.01.03.20016451 AU - Craig Versek AU - S. Mohammad Ali Banijamali AU - Peter J. Bex AU - Kameran Lashkari AU - Sagar V. Kamarthi AU - Srinivas Sridhar Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/01/10/2020.01.03.20016451.abstract N2 - Delayed Dark Adapted vision Recovery (DAR) is a biomarker for Age-related Macular Degeneration (AMD); however, its measurement is burdensome for patients and examiners. We developed a portable, wireless, quick-setup system that employs a headset with a smartphone to deliver and analyze controlled dichoptic photobleach and pattern reversal stimuli, and with custom electroencephalography (EEG) electrodes, to measure objective Dark Adapted Visual Evoked Potentials (DAVEP) at multiple locations of the visual field in one comfortable 20-minute session, without requiring subject reporting. DAVEP responses post photobleach (up to 15 minutes), were measured concurrently in both eyes of 13 patients with AMD and 8 others not diagnosed with AMD. New unexpected features were observed in the DAVEP responses at high latencies to scotopic stimulus intensities. The amplitude recovery of the DAVEP response was significantly delayed in AMD patients compared with controls. We developed DAVEP1 scores, a simple metric for DAR, using it to successfully identify all 100% of AMD subjects and correctly classify 90% of subject eyes. Deficits in DAR in patients with AMD can be identified with this objective VEP based system using the DAVEP1 metric, a promising new objective biomarker for this disease that can be easily tested in a clinic.Competing Interest StatementSK None. KL None. SAB None. PB Research Support, NeuroFieldz Inc, Newton, MA. CV Research Support, NeuroFieldz Inc, Newton, MA. Patent, Northeastern University SS Research Support, NeuroFieldz Inc, Newton, MA. Patent, Northeastern UniversityFunding StatementWork partially supported by grant HHS-1R41AG057250-01.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data sets may be made available upon request to the corresponding author via email (cversek@gmail.com). ER -